Harnett PR - Search Results

1

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.

Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N; Australian Ovarian Cancer Study Group; Harnett PR, Bowtell DDL, deFazio A. Lindemann K, et al. Among authors: harnett pr. Gynecol Oncol. 2018 Aug;150(2):239-246. doi: 10.1016/j.ygyno.2018.05.020. Epub 2018 May 26. Gynecol Oncol. 2018. PMID: 29807697

2

Cisplatin plus VP 16-213 in advanced ovarian carcinoma.

Harnett PR, Bell DR, Hillcoat BL, Woods RL, Levi JA, Rome RM, Campbell JC, Tattersall MH. Harnett PR, et al. Gynecol Oncol. 1988 Jun;30(2):159-62. doi: 10.1016/0090-8258(88)90019-4. Gynecol Oncol. 1988. PMID: 3371739

3

Drug resistance in clinical practice: patterns of treatment failure in patients receiving systemic therapy for advanced breast cancer.

Harnett PR, Tattersall MH, Coates AS, van Couten R, Forbes J. Harnett PR, et al. Eur J Cancer Clin Oncol. 1987 Nov;23(11):1601-5. doi: 10.1016/0277-5379(87)90437-8. Eur J Cancer Clin Oncol. 1987. PMID: 3428331

4

Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines.

Segelov E, Mann G, deFazio A, Harnett PR. Segelov E, et al. Among authors: harnett pr. Mutat Res. 1998 Jun;407(3):243-52. doi: 10.1016/s0921-8777(98)00006-8. Mutat Res. 1998. PMID: 9653450

5

Integrated multimodality therapy for embryonal rhabdomyosarcoma of the lower genital tract in postpubertal females.

Hahlin M, Jaworski RC, Wain GV, Harnett PR, Neesham D, Bull C. Hahlin M, et al. Among authors: harnett pr. Gynecol Oncol. 1998 Jul;70(1):141-6. doi: 10.1006/gyno.1998.4983. Gynecol Oncol. 1998. PMID: 9698493 Review.

6

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

Friedlander M, Millward MJ, Bell D, Bugat R, Harnett P, Moreno JA, Campbell L, Varette C, Ripoche V, Kayitalire L. Friedlander M, et al. Ann Oncol. 1998 Dec;9(12):1343-5. doi: 10.1023/a:1008469212268. Ann Oncol. 1998. PMID: 9932166 Free article. Clinical Trial.

7

Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line--a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia.

Guminski AD, Harnett PR, deFazio A. Guminski AD, et al. Among authors: harnett pr. Cancer Chemother Pharmacol. 2001 Sep;48(3):229-34. doi: 10.1007/s002800100279. Cancer Chemother Pharmacol. 2001. PMID: 11592345

8

Scientists and clinicians test their metal-back to the future with platinum compounds.

Guminski AD, Harnett PR, deFazio A. Guminski AD, et al. Among authors: harnett pr. Lancet Oncol. 2002 May;3(5):312-8. doi: 10.1016/s1470-2045(02)00733-7. Lancet Oncol. 2002. PMID: 12067809 Review.

9

Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma.

Balleine RL, Earls PJ, Webster LR, Mote PA, deFazio A, Harnett PR, Clarke CL. Balleine RL, et al. Among authors: harnett pr. Int J Gynecol Pathol. 2004 Apr;23(2):138-44. doi: 10.1097/00004347-200404000-00008. Int J Gynecol Pathol. 2004. PMID: 15084842

10

A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer.

Rischin D, Phillips KA, Friedlander M, Harnett P, Quinn M, Richardson G, Martin A. Rischin D, et al. Gynecol Oncol. 2004 May;93(2):417-21. doi: 10.1016/j.ygyno.2004.01.037. Gynecol Oncol. 2004. PMID: 15099955 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page